The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 01, 2022

Filed:

Jan. 21, 2020
Applicant:

Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);

Inventors:

Brian Bettencourt, Cambridge, MA (US);

Shanthi Ganesh, East Hanover, NJ (US);

Elizabeth George, Cambridge, MA (US);

Dieter Huesken, Basel, CH;

Stuart Milstein, Cambridge, MA (US);

Jonathan Solomon, Cambridge, MA (US);

Emily Thomas, Cambridge, MA (US);

Ivanka Toudjarska, Cambridge, MA (US);

Jennifer Tullai, Cambridge, MA (US);

Jan Weiler, Cambridge, MA (US);

Assignee:

Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 31/7105 (2006.01); A61K 31/7115 (2006.01); A61K 31/712 (2006.01); A61K 31/7125 (2006.01); A61K 31/713 (2006.01);
U.S. Cl.
CPC ...
C12N 15/113 (2013.01); A61K 31/712 (2013.01); A61K 31/713 (2013.01); A61K 31/7105 (2013.01); A61K 31/7115 (2013.01); A61K 31/7125 (2013.01); A61K 45/06 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/342 (2013.01); C12N 2310/351 (2013.01); C12N 2320/30 (2013.01);
Abstract

The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preeclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.


Find Patent Forward Citations

Loading…